AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
AIM ImmunoTech spotlighted a BioTuesdays feature on its strategy to use Ampligen as a maintenance therapy in metastatic pancreatic cancer following first-line chemotherapy. Final dosing is complete in the Phase 2 DURIPANC trial pairing Ampligen with AstraZeneca's Imfinzi, with primary and secondary endpoints still pending.
Key figures
- Drug Name
- Ampligen (rintatolimod)
- Phase Of Trial
- Phase 2
- Nlr threshold
- 4.5
- Npp nlr subgroup patients
- 39
- Npp median overall survival months
- 34.8
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.